Drugs / TWP-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04871347 | Aug 2021 → Jun 2023 | neoplasm | Shandong TheraWisdom Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04871334 | Feb 2021 → Oct 2022 | melanoma, urothelial carcinoma | Shandong TheraWisdom Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TWP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871347 ↗ |
| Route | Intravenous | “IV infusion Q2W for 4 weeks (28-day cycles)” NCT04871334 ↗ |